Putting #SPICE3 together with #A2Btrial it does now seem hard to justify the use of these drugs in the ICU. I’m not very compelled by the arguments that we should try again with even higher doses given the side effect profile of these agents. #CCR24
@DocEd Yes I agree. Important to remember the opportunity cost when the community chooses which research to support. The effort and attention of the global ICM community is a precious resource .
Ed Palmer
Kenneth Baillie